WO2004111249A2 - Protein constructs containing caspase recognition sites - Google Patents
Protein constructs containing caspase recognition sites Download PDFInfo
- Publication number
- WO2004111249A2 WO2004111249A2 PCT/EP2004/006225 EP2004006225W WO2004111249A2 WO 2004111249 A2 WO2004111249 A2 WO 2004111249A2 EP 2004006225 W EP2004006225 W EP 2004006225W WO 2004111249 A2 WO2004111249 A2 WO 2004111249A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- virus
- protein
- nucleotide sequence
- vector
- nsl
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 70
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 67
- 102000011727 Caspases Human genes 0.000 title claims abstract description 43
- 108010076667 Caspases Proteins 0.000 title claims abstract description 43
- 241000700605 Viruses Species 0.000 claims abstract description 75
- 239000013598 vector Substances 0.000 claims abstract description 29
- 239000002773 nucleotide Substances 0.000 claims abstract description 24
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 24
- 230000002238 attenuated effect Effects 0.000 claims abstract description 17
- 229960005486 vaccine Drugs 0.000 claims abstract description 12
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 11
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract 4
- 210000004027 cell Anatomy 0.000 claims description 42
- 210000003501 vero cell Anatomy 0.000 claims description 38
- 238000003776 cleavage reaction Methods 0.000 claims description 30
- 230000007017 scission Effects 0.000 claims description 29
- 241000712461 unidentified influenza virus Species 0.000 claims description 20
- 230000003612 virological effect Effects 0.000 claims description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 102000014150 Interferons Human genes 0.000 claims description 9
- 108010050904 Interferons Proteins 0.000 claims description 9
- 229940079322 interferon Drugs 0.000 claims description 9
- 230000001323 posttranslational effect Effects 0.000 claims description 9
- 230000002950 deficient Effects 0.000 claims description 7
- 238000001727 in vivo Methods 0.000 claims description 7
- 108010067390 Viral Proteins Proteins 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 230000009385 viral infection Effects 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 101710192141 Protein Nef Proteins 0.000 claims description 3
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims description 3
- 230000000890 antigenic effect Effects 0.000 claims description 3
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 2
- 201000004792 malaria Diseases 0.000 claims description 2
- 108010077805 Bacterial Proteins Proteins 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000013603 viral vector Substances 0.000 abstract description 9
- 241000699670 Mus sp. Species 0.000 description 18
- 208000015181 infectious disease Diseases 0.000 description 17
- 210000004072 lung Anatomy 0.000 description 16
- 102000006992 Interferon-alpha Human genes 0.000 description 14
- 108010047761 Interferon-alpha Proteins 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 14
- 206010022000 influenza Diseases 0.000 description 13
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 12
- 238000003780 insertion Methods 0.000 description 10
- 230000037431 insertion Effects 0.000 description 10
- 208000037262 Hepatitis delta Diseases 0.000 description 9
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 208000029570 hepatitis D virus infection Diseases 0.000 description 9
- 230000010076 replication Effects 0.000 description 9
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 229940123169 Caspase inhibitor Drugs 0.000 description 6
- 101150076514 NS gene Proteins 0.000 description 6
- 108700026244 Open Reading Frames Proteins 0.000 description 6
- 208000037797 influenza A Diseases 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000004570 RNA-binding Effects 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 241000724709 Hepatitis delta virus Species 0.000 description 4
- 241000712431 Influenza A virus Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- AVWQQPYHYQKEIZ-UHFFFAOYSA-K trisodium;2-dodecylbenzenesulfonate;3-dodecylbenzenesulfonate;4-dodecylbenzenesulfonate Chemical compound [Na+].[Na+].[Na+].CCCCCCCCCCCCC1=CC=C(S([O-])(=O)=O)C=C1.CCCCCCCCCCCCC1=CC=CC(S([O-])(=O)=O)=C1.CCCCCCCCCCCCC1=CC=CC=C1S([O-])(=O)=O AVWQQPYHYQKEIZ-UHFFFAOYSA-K 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 102000004091 Caspase-8 Human genes 0.000 description 3
- 108090000538 Caspase-8 Proteins 0.000 description 3
- 102000004039 Caspase-9 Human genes 0.000 description 3
- 108090000566 Caspase-9 Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- MIFGOLAMNLSLGH-QOKNQOGYSA-N Z-Val-Ala-Asp(OMe)-CH2F Chemical compound COC(=O)C[C@@H](C(=O)CF)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1 MIFGOLAMNLSLGH-QOKNQOGYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 208000037798 influenza B Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102100023033 Cyclic AMP-dependent transcription factor ATF-2 Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000197304 H2N2 subtype Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000974934 Homo sapiens Cyclic AMP-dependent transcription factor ATF-2 Proteins 0.000 description 1
- 101000997829 Homo sapiens Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 101000802734 Homo sapiens eIF5-mimic protein 2 Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091034135 Vault RNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- SIIZPVYVXNXXQG-KGXOGWRBSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(3s,4r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Polymers C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)OC2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OCC([C@@H](O)[C@H]1O)OC1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-KGXOGWRBSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 102100035859 eIF5-mimic protein 2 Human genes 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 108700029658 influenza virus NS Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16141—Use of virus, viral particle or viral elements as a vector
- C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16161—Methods of inactivation or attenuation
- C12N2760/16162—Methods of inactivation or attenuation by genetic engineering
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention is in the field of recombinant technology and viral vaccine production and relates to viral protein constructs and to recombinant viruses containing such constructs wherein the protein constructs contain caspase recognition sites for posttranslational cleavage by caspase enzymes during infection cycles in a mammalian host or host cell.
- the invention further relates to a method of making such protein constructs and to their use, particularly as part of a vaccine.
- Influenza virus infection provokes the activation of caspase proteases and triggers subsequent apoptosis in infected cells (Alnemri et al . , 1996).
- Active caspases can cleave the proteins at the recognition sites which may consist of as little as a sequence of just 4 amino acids.
- NP protein of human influenza viruses A and B was found to be cleaved in the infected cells at the amino acid sequences EXD/X and DXD/X, typical for caspase proteases (Zhirnov et al., 1999).
- recombinant protein constructs intended for posttranslational cleavage usually requires the provision of one or more cleavage sites within the constructs in order to allow for proteases to specifically cleave the amino acid sequences at these predetermined cleavage sites.
- influenza virus as viral vectors, in contrast to other systems such as adenoviral vectors or retroviruses, is that it does not contain a DNA intermediate and therefore is not able to integrate into the host's chromosomes.
- live influenza virus vaccines have been developed and licensed for humans and could thus also be used for the expression of additional antigens.
- the NSl protein In primary infected cells, one of the main strategies of the influenza virus is to inhibit IFN ⁇ / ⁇ signaling to the neighboring cells, which can induce their antiviral state.
- the NSl protein has been suggested to perform several important accessory functions for the effective replication of the virus in its host. First, by the activity of its carboxy-terminal domain, the NSl protein is able to inhibit the host mRNA' s processing mechanisms. Second, it facilitates the preferential translation of viral mRNA by direct interaction with the cellular translation initiation factor eIF4GI.
- the NSl protein is able to prevent the activation of IFN-inducible dsRNA activated kinase (PKR) , 2 ' , 5 ' -oligoadenylate synthetase system, and cytokine transcription factors such as NF- ⁇ B or IRF 3 and c- Jun/ATF2.
- PLR IFN-inducible dsRNA activated kinase
- cytokine transcription factors such as NF- ⁇ B or IRF 3 and c- Jun/ATF2.
- the NSl protein inhibits the expression of INF- ⁇ and INF- ⁇ genes, delays the development of apoptosis in the infected cells and prevents the formation of the antiviral state in the neighboring cells.
- the function of the NSl protein as an IFN- ⁇ / ⁇ antagonist was proven by the construction of several NS mutants, bearing C-terminal deletions which showed impaired growth properties in IFN competent cells such as MDCK, embryonated chicken eggs or mouse lungs, but had no attenuation effect in IFN deficient hosts such as Vero cells or PKR knock out mice. It was found, that an influenza NS mutant coding for just the first N-terminal 125 amino acids was only slightly attenuated in IFN competent systems, while mutants carrying shorter versions, respectively less than 80 aa of the NSl protein, were dramatically attenuated in MDCK cells and mice.
- the present inventors established a reverse genetic system in Vero cells in which influenza virus NS transfectants could be obtained using human IFN- ⁇ as a selection drug against an IFN sensitive helper virus.
- the high efficiency of this system allowed to rescue a genetically stable influenza virus expressing a protein of interest (POI) such as, e.g. GFP, from the NSl reading frame .
- POI protein of interest
- the present inventors generated influenza A viruses expressing a recombinant NSl protein, containing caspase recognition sites inserted at or after amino acid position 125. This insertion provided a mechanism of post-translational cleavage of the NSl protein into two parts at a late time point of infection. When general caspase inhibitor Z-VAD-FMK was added, cleavage was prevented.
- each recognition site may typically consist of no more than 4 amino acids.
- the invention further relates to recombinant viruses containing any such vector.
- the vaccines of the present invention may be designed for application in the prophylaxis or therapy of any viral infections by selecting suitable antigenic determinants of viral proteins, particularly envelope proteins, for insertion into the heterologous viral vector construct referred to above.
- the present invention allows for the efficient manufacture of correctly cleaved peptides or proteins of interest as well as for the manufacture of attenuated live vaccines based on viruses containing recombinant viral vectors that encode heterologous peptides or proteins.
- the present invention relates to a live vaccine based on attenuated, particularly temperature sensitive (ts), influenza A or B virus containing a vector system that encodes a truncated NSl protein together with caspase recognition sites and an antigenic determinant of an HIV-I protein, e.g.
- influenza A and B viruses which express a recombinant NSl protein (Fig.l) containing a pair of different caspase recognition sites (CRS) , each consisting of 4 amino acids and spaced apart by a glycine residue (G) in between the two sites, thus making up the aa sequence DIDGGETDG (SEQ ID NO 1) .
- This sequence can be cleaved by caspase 3 and probably by other caspases and thus ensures postranslational cleavage of the foreign sequence (i.e. peptide or protein of interest, POI) from the N-terminal part of the NSl protein.
- Previous constructs using 18 aa of the 2A cleavage site of piccornavirus did not or not satisfactorily work in some of the POI expressing vectors.
- NSl-GFP virus was growing in IFN competent cells it did not or only poorly replicate in wild type C57/bl mice, much like the delNSl virus which completely lacks the NSl ORF.
- PKR knock out mice for the wild type mice replication of NSl-GFP virus in the lungs proceeded up to a titer of equal or more than 10 4 PFU/g of lung tissue, as was also the case with delNSl virus.
- the virus did not lose its capacity to express GFP.
- the GFP insert may have some negative influence on the formation of the NSl dimers, making NSl function to be less efficient and therefore promoting the activation of PKR.
- influenza virus can be engineered in such a way that foreign sequences which are even longer than the NSl protein itself can be expressed from the NSl reading frame and that such recombinant ' viruses can be successfully maintained and propagated to high titers in IFN deficient substrates such as Vero cells .
- This new approach could be a promising strategy for the generation of live antiviral, preferably influenza virus- based, vaccines and vectors, and most preferably using NSl truncation technology as disclosed, e.g., in WO 01/64860, wherein NSl truncation occurs at or after aa position 125 by deletion of the N-terminal part of the NSl sequence or by insertion of one or more desired POI sequences after aa position 125.
- the vector constructs and viruses containing such contructs according to the present invention can be used as tools for screening of antiviral drugs against desired antigens, and where the POI is a marker substance, e.g. a fluorescent dye, also for tracking virus infections in animals and human subjects.
- FIG.l Schematic drawing of the structure of a truncated recombinant NSl protein containing caspase recognition sites (CRS) .
- FIG.2 Post-translational cleavage of the recombinant viral protein NSl-Caspase-ELDKWAS-ILl .
- FIG.3 Virus yields in MDCK cells at 39°C after treatment with different caspase inhibitors.
- Ordinate: viral titers expressed in pfu/ml; abscisse: different caspase inhibitors; "w/o” without; "general” means inhibitor Z-VAD FMK, which inhibits all caspases .
- Fig.5 Cleavage of recombinant NSl-GFP protein in infected cells. MDCK cells were infected with NSl-GFP virus in the presence (lanes 2 and 3) and absence (lane 1 and
- A NSl-GFP fusion protein
- B cleaved GFP
- C cleaved NSl.
- Fig.6 Viral growth in mouse lungs.
- PKR +/+ mice or PKR ⁇ /- mice were infected intranasally with 5*10 4 PFU/animal of the transfectant NSl-GFP virus.
- mouse lungs were titrated using a limiting dilution assay on Vero cells and shown as geometric mean titer.
- Example 1 Preparation of recombinant negative strand influenza A viruses
- the sequence of CCS was inserted into the NSl protein ORF, at the position 400nt followed by the sequence of the protein of interest (designated LEI) consisting of HA leader peptide + ELDKWAS (SEQ ID NO 3) peptide sequence from GP-41 of HIV-1+ IL-I nanopeptide.
- LEI sequence of the protein of interest
- ELDKWAS SEQ ID NO 3
- a final recombinant plasmid was constructed harboring a mutated influenza A/PR/8/34 NS gene flanked by the human polymerase I (Poll) promoter and Hepatitis Delta Virus (HDV) genomic ribozyme sequences.
- This plasmid clone was used for the transfection of Vero cells. Syntheic chimeric NS gene transcribed by Poll polymerase in vivo (Vero cells) was rescued using special influenza virus helper viruses: PR8 DeINS (rf. WO
- Suitable recombinant protein constructs according to the present invention are represented in general by the schematic drawing of FIG. 1, while the invention disclosed herein is explicitly exemplified for the following recombinant protein construct (SEQ ID NO 3) that was prepared following the aforementioned protocol:
- Example 2 Cleavage of a recombinant protein construct containing CRS
- recombinant protein construct described in Example 1 was further subjected to post-translational cleavage by caspase enzymes.
- Fig.2 mirrors the results of the western blot analysis, showing that the recombinant NSl protein containing CRS was efficiently cleaved by the activated caspases after 12 hours of infection (lane 4 and 5) .
- caspase inhibitor VAD was added (lane 6) protein cleavage was abolished.
- MDCK cells were infected with recombinant influenza Sg/NSl-Caspase-ELDKWAS-ILl virus and analysed by western blot using mouse anti-NSl serum.
- Lane 1 shows the size of NS1/125 protein, containing just 125 NSl specific N- terminal amino acids remaining in the present constructs .
- Lane 3 and Lane 4 show the cleaved and uncleaved forms of the recombinant protein at 4 hours (lane 3) and 10 hours (lane 4) after infection; lane 5 shows cleavage of the NSl-Caspase-ELDKWAS-ILl protein 12 hours after infection in Vero cells; lane 6 shows the result when caspase inhibitor Z-VAD-FMK (Supplier: R&D Systems) was added to the maintenance medium, the result being failure of cleavage of the NSl-Caspase-ELDKWAS-ILl protein 12 hours after infection of Vero cells.
- caspase inhibitor Z-VAD-FMK Syplier: R&D Systems
- HlNl recombinant influenza A
- HlNl recombinant influenza A virus comprising the caspase recognition sites PR8-NS-Caspase-LEI
- HlNl control virus
- Infected cells were incubated at two temperatures 37°C and 39 0 C for 24 hours.
- Caspase inhibitors were added to the culture media at a concentration of 0.25 ⁇ M. Viral yields were measured by the titration on Vero cells at the permissive temperature of 37 0 C.
- PR8-NS2A-LEI HlNl (control) 5x10 6 3xlO 6 IxIO 6 2xlO 4
- Caspase 8 and 9 are probably involved in the mechanism of this (ts) phenotype expression, because addition of caspase 8 and 9 as well as of the general caspase inhibitor to the tissue culture media have increased the viral titers by a factor of more than 100 as compared to the control groups where DMSO solution without inhibitor or other caspase inhibitors were added (see Fig.3).
- influenza A and B recombinant viruses containing the CRS DIDGGETDG appeared to be attenuated in mice after intranasal immunization.
- Fig.4 shows the growth curves of two similar recombinant influenza viruses, differing primarily in the presence or absence of CRS.
- the control virus PR8-NS-2A- LEI (HlNl) does not have this site and replicates efficiently up to 3.5 log/g in the lung tissues.
- the experimental virus PR8-NS-caspase-LEI containing CRS displays very weak replication in the lungs and is more than 100 times attenuated in the experimental group of mice .
- Example 5 Rescue of influenza virus expressing gfp from the NSl reading frame
- Vero and MDCK cell lines originated from the American Type Culture Collection (ATCC) . Vero cells were adapted to and further cultivated in DMEM/Ham' s F12 (Biochrom F4815) with 4 mM L-glutamine and protein-free supplement. MDCK cells were cultivated in DMEM/Ham' s F12 medium containing 2 % heat inactivated fetal calf serum (FCS, HyClone SH30071) and 4 mM L-glutamine. Influenza virus A/PR/8/34 (HlNl)
- NS1-125 and A/PR8/NSl-del40-80 were obtained in Vero cells by using the transfection protocol as described in Egorov et al.,1998. All viruses were grown and titrated in Vero cells at 37° C.
- Viral RNA was extracted from influenza PR8, reverse transcribed and served as a template for subsequent amplification of the NS gene by PCR.
- the NS sequence was blunt end cloned between the Poll promoter and hepatitis delta virus (HDV) genomic ribozyme and designated as pPolI-NS-HDV.
- GFP encoding sequence (Quantum' s SuperGloTM GFP, extracted from Vector pQBI25-fcl, Qbiogene) into plasmid pPol-NS125Casp-HDV downstream the CRS resulted in the plasmid pPol-NS-Casp-GFP-HDV.
- the expression plasmids for PBl, PB2, PA and NP influenza proteins were obtained by cloning the corresponding PR8 genes into the vector pTriEx-1 (Novagene) under the chicken actin promoter; they were designated pTriEx-PBl, pTriEx-PB2, pTriEx-PA and pTriEx-NP, respectively.
- Vero cells were transfected with l ⁇ g of each plasmid pPol-NS-Casp-GFP-HDV, pTriEx-NP, pTriEx-PA, pTriEx-PBl and pTriEx-PB2 using the nucleofection technique (Amaxa) , according to the manufacturer's instruction manual. 24 hours later, cells were examined for GFP expression and infected with delNSl helper virus
- mice lungs Viral replication in mice lungs:
- mice Four to six weeks old C57BL/6 mice or PKR knock out mice (PKR-/-) , which were derived from C57BL/6 mice by the targeted deletion of PKR (Yang et al., 1995) were infected intranasally (i.n.) with 5*10 4 PFU/animal of the virus under ether anesthesia. At day two, mice were sacrificed and lungs aseptically removed. A 10% tissue extract in PBS was prepared by grinding the tissue sample with a rotor homogenizer. The suspension was centrifuged at 2,000 g for five minutes and the viral yield of the supernatants was determined by limiting dilution assay in Vero cells.
- the membrane was either incubated for one hour with anti-mouse alkaline phosphatase or anti- rabbit peroxidase labeled conjugate (Sigma) diluted 1:40,000 in TPBS containing 1% of skim milk.
- the blots were developed in staining buffer (100 mM Tris HCl/ 100 mM NaCl; 5 mM MgCl 2 , pH 9.5) with nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate or by ECL plus Western Blotting Detection system (Amersham) for chemoluminiscence, respectively.
- Vero cells were infected with the wild type PR8 virus or three different NS mutants containing either only 125 N-terminal aa (NS1-125), lacking NSl ORF (delNSl) or harboring a 40 aa deletion (NSl-del40-80) in the N-terminal part of the molecule (Table 2) .
- Table 2 shows the growth of recombinant virus mutants containing different NSl truncations on Vero cells in the absence or presence of externally added human IFN- ⁇ .
- Titers of influenza PR8 virus and NS mutants grown in the presence or absence of human IFN- ⁇ in Vero cells were determined 36 h post infection using a plaquing assay on Vero cells.
- the infected cells were incubated either without addition of human IFN- ⁇ to the cell culture medium or in the presence of 3 U/ml human IFN- ⁇ , whereupon the viral titers were compared 36 h post infection.
- mutants delNSl and NSl-del40-80 containing an impaired RNA binding/dimerization domain were dramatically attenuated with regard to growth under the pressure of IFN- ⁇ , whereas the wild type virus as well as the NS1-125 mutant containing an intact RNA binding domain showed almost similar titers when incubated in the presence or absence of IFN- ⁇ (Tab.2).
- the first N-terminal 125 amino acids of the NSl protein may possibly serve as a resistance factor responsible for antagonizing IFN action.
- Vero cells were transfected with plasmids expressing the components of the influenza RNP complex and the plasmid pPol-NS-Casp-GFP-HDV encoding chimeric vRNA in which GFP was cloned as the protein of interest (POI) into the NSl reading frame after aa 125, according to the general concept depicted in Fig.l.
- an artificial caspase recognition site DIDGGETDG was introduced between those two proteins in order to provide posttranslational separation of the molecules.
- Transfected cells were infected with an IFN-sensitive helper virus (delNSl) and the virus yield was harvested 48 h post infection. This yield contained at least 10 2 PFU/ml progeny of the "fluorescent virus” and 10 5 PFU/ml of the helper virus, determined by limiting dilution assay in
- Vero cells without IFN- ⁇ treatment Two passages in Vero cells in the presence of IFN- ⁇ were performed to enrich the population of the transfectant virus and a pure GFP expressing plaque was isolated. After a further two rounds of plaque purification in Vero cells, in which plaques were routinely examined for GFP expression, a pure clone of GFP expressing virus was isolated and designated as A/PR8/NS1-125GFP (NSl-GFP) .
- NSP A/PR8/NS1-125GFP
- Western blot analysis it was confirmed that insertion of the CRS indeed resulted in posttranslational cleavage of the GFP from the N-terminal part of the NSl protein (Fig.5).
- Addition of general caspase inhibitor Z- VAD-FMK (R&D Systems) to the medium inhibited cleavage, thus confirming that cleavage occurred due to host cells caspase activity.
- the recombinant NSl-GFP strain had an IFN resistant phenotype and was capable of replicating in MDCK cells and ten days old embryonated chicken eggs as efficient as in Vero cells up to titers of 10 6 -10 7 PFU/ml.
- the genetic stability of the construct was not equal in IFN deficient and in IFN competent cell substrates.
- passages in MDCK cells caused evolution of NSl-GFP deletion mutants at a fairly high rate accompanied by the loss of GFP expression after several passages.
- Virus NSl-GFP revealed a full attenuation in the wild type mice (C57BL/6) as compared to the NS125 mutant, which reached a titer of 5*10 4 PFU/g in the lung tissues two days post infection (Fig.6).
- the infection of PKR knock out (PKR-/-) mice previously shown to support the replication of the delNSl virus, resulted in the replication of the GFP expressing vector in lung tissues to 4*10 4 PFU/g, detected two days post infection.
- the virus was still expressing GFP as confirmed by titration in Vero cells.
Abstract
The present invention relates to a nucleotide sequence encoding a recombinant protein product wherein the nucleotide sequence contains at least one sequence that encodes one or more caspase recognition sites and that is located in between and links together a first part of the nucleotide sequence encoding a first part of the protein product and a second part of the nucleotide sequence encoding a second part of the protein product. The invention further relates to viral vectors and recombinant viruses containing said nucleotide sequence, as well as to vaccines, particularly attenuated live vaccines, and compositions comprising said vectors or viruses.
Description
PROTEIN CONSTRUCTS CONTAINING CASPASE RECOGNITION SITES
FIELD OF INVENTION
The present invention is in the field of recombinant technology and viral vaccine production and relates to viral protein constructs and to recombinant viruses containing such constructs wherein the protein constructs contain caspase recognition sites for posttranslational cleavage by caspase enzymes during infection cycles in a mammalian host or host cell. The invention further relates to a method of making such protein constructs and to their use, particularly as part of a vaccine.
TECHNICAL BACKGROUND
Influenza virus infection provokes the activation of caspase proteases and triggers subsequent apoptosis in infected cells (Alnemri et al . , 1996). Active caspases can cleave the proteins at the recognition sites which may consist of as little as a sequence of just 4 amino acids. For example, NP protein of human influenza viruses A and B was found to be cleaved in the infected cells at the amino acid sequences EXD/X and DXD/X, typical for caspase proteases (Zhirnov et al., 1999).
The design of recombinant protein constructs intended for posttranslational cleavage usually requires the provision of one or more cleavage sites within the constructs in order to allow for proteases to specifically cleave the amino acid sequences at these predetermined cleavage sites. Reference is made to Example 1 and Figures 2 and 3 of WO 01/64860, wherein viral vector systems are disclosed which encode a heterologous amino acid sequence comprising a truncated NSl protein of influenza A virus followed by
the 2A cleavage site of piccornavirus, and further comprising one or more subsequent amino acid sequences of desired peptides or proteins, e.g. the Nef protein of HIV- 1, the ELDKWA sequence of gp 41 of HIV-I, or an interleukin, optionally preceded by a leader sequence, and optionally followed by an anchor sequence. It turned out, however, that the 2A cleavage site was not perfectly suitable for all heterologous constructs prepared by the present inventors so far. It was therefore an objective of the present invention to overcome this drawback by providing an improved viral vector system that allows for superior cleavage and an increased yield of correctly cleaved protein products.
One of the advantages of using the influenza virus as viral vectors, in contrast to other systems such as adenoviral vectors or retroviruses, is that it does not contain a DNA intermediate and therefore is not able to integrate into the host's chromosomes. In addition, live influenza virus vaccines have been developed and licensed for humans and could thus also be used for the expression of additional antigens.
In primary infected cells, one of the main strategies of the influenza virus is to inhibit IFNα/β signaling to the neighboring cells, which can induce their antiviral state. In this context, the NSl protein has been suggested to perform several important accessory functions for the effective replication of the virus in its host. First, by the activity of its carboxy-terminal domain, the NSl protein is able to inhibit the host mRNA' s processing mechanisms. Second, it facilitates the preferential translation of viral mRNA by direct interaction with the cellular translation initiation factor eIF4GI. Third, by
binding to dsRNA and interaction with putative cellular kinase (s), the NSl protein is able to prevent the activation of IFN-inducible dsRNA activated kinase (PKR) , 2 ' , 5 ' -oligoadenylate synthetase system, and cytokine transcription factors such as NF-κB or IRF 3 and c- Jun/ATF2. As a result thereof, the NSl protein inhibits the expression of INF-α and INF-β genes, delays the development of apoptosis in the infected cells and prevents the formation of the antiviral state in the neighboring cells.
The function of the NSl protein as an IFN-α/β antagonist was proven by the construction of several NS mutants, bearing C-terminal deletions which showed impaired growth properties in IFN competent cells such as MDCK, embryonated chicken eggs or mouse lungs, but had no attenuation effect in IFN deficient hosts such as Vero cells or PKR knock out mice. It was found, that an influenza NS mutant coding for just the first N-terminal 125 amino acids was only slightly attenuated in IFN competent systems, while mutants carrying shorter versions, respectively less than 80 aa of the NSl protein, were dramatically attenuated in MDCK cells and mice.
When testing the ability of several influenza A NSl- deletion mutants to circumvent an artificial antiviral state of Vero cells due to external addition of human IFN- α, it was found that NS mutants encoding the N-terminal 125 amino acids of the NSl protein but not mutants with an impaired RNA binding domain like delNSl completely lacking the NSl ORF, were fully resistant to the interferon action and were replicating as efficiently as the wild type virus under the same conditions. Thus, it could be demonstrated that the influenza virus is able to circumvent the
antiviral state of the interferon treated cells most likely by the activity of the NSl protein RNA binding domain .
BRIEF DESCRIPTION OF THE INVENTION
Based on this finding, the present inventors established a reverse genetic system in Vero cells in which influenza virus NS transfectants could be obtained using human IFN-α as a selection drug against an IFN sensitive helper virus. The high efficiency of this system allowed to rescue a genetically stable influenza virus expressing a protein of interest (POI) such as, e.g. GFP, from the NSl reading frame .
To achieve this goal, the present inventors generated influenza A viruses expressing a recombinant NSl protein, containing caspase recognition sites inserted at or after amino acid position 125. This insertion provided a mechanism of post-translational cleavage of the NSl protein into two parts at a late time point of infection. When general caspase inhibitor Z-VAD-FMK was added, cleavage was prevented.
It was further demonstrated by corresponding experiments that rescued viruses of HlNl and H2N2 subtypes carrying such a recombinant NS gene were not restricted in growth on interferon deficient Vero cells whereas surprisingly, a temperature-sensitive (ts) phenotype was observed on MDCK cells. It was possible, however, to compensate this temperature sensitivity by treatment of infected cells with caspase 8 and 9 inhibitors. Moreover, both types of viruses were significantly attenuated in mice after intranasal immunization, resulting in at least a 103-fold
reduction of viral titers in the lungs as compared to immunizations with the control virus comprising a 2A cleavage site instead of the caspase cleavage sites.
It is therefore an object of the invention to provide a method for the manufacture of recombinant peptides or proteins, particularly recombinant viral peptides or proteins, wherein the method comprises providing a suitable viral vector system comprising at least two amino acid sequences linked by a protein recognition site, said protein recognition site being a caspase recognition site, preferably a combination of 2 or more identical or different caspase recognition sites, and expressing the recombinant protein or proteins, as the case may be, in a suitable expression system, preferably a mammalian host cell, wherein during or after expression cleavage of the expressed protein products by one or more caspase enzymes present therein or added thereto may take place. According to the invention, each recognition site may typically consist of no more than 4 amino acids.
It is another object of the present invention to provide viral vectors encoding one or more heterologous peptides or proteins, wherein the viral vector comprises nucleotide sequences encoding a first peptide or protein of interest, followed by a nucleotide sequence encoding one or more caspase recognition sites, and a nucleotide sequence encoding a second peptide or protein of interest. The invention further relates to recombinant viruses containing any such vector.
It is another object of the invention to provide a vaccine comprising a virus that contains a vector according to the present invention. The vaccines of the present invention may be designed for application in the prophylaxis or
therapy of any viral infections by selecting suitable antigenic determinants of viral proteins, particularly envelope proteins, for insertion into the heterologous viral vector construct referred to above.
The present invention allows for the efficient manufacture of correctly cleaved peptides or proteins of interest as well as for the manufacture of attenuated live vaccines based on viruses containing recombinant viral vectors that encode heterologous peptides or proteins. In a preferred embodiment, the present invention relates to a live vaccine based on attenuated, particularly temperature sensitive (ts), influenza A or B virus containing a vector system that encodes a truncated NSl protein together with caspase recognition sites and an antigenic determinant of an HIV-I protein, e.g. the (L)ELDKWA(S) sequence of gp41 (SEQ ID NOs 2, 3, 4, 5) , or part of the Nef protein of HIV-I, or any other peptide or protein of interest from HIV or from any source other than HIV including but not limited to hepatitis, tuberculosis, malaria or tumor antigens .
DETAILED DESCRIPTION OF THE INVENTION
In order to study caspase-dependent cleavage of an intracellular synthesized recombinant viral protein the present inventors generated influenza A and B viruses which express a recombinant NSl protein (Fig.l) containing a pair of different caspase recognition sites (CRS) , each consisting of 4 amino acids and spaced apart by a glycine residue (G) in between the two sites, thus making up the aa sequence DIDGGETDG (SEQ ID NO 1) . This sequence can be cleaved by caspase 3 and probably by other caspases and thus ensures postranslational cleavage of the foreign sequence (i.e. peptide or protein of interest, POI) from
the N-terminal part of the NSl protein. Previous constructs using 18 aa of the 2A cleavage site of piccornavirus did not or not satisfactorily work in some of the POI expressing vectors.
Surprisingly, it was also found that recombinant influenza viruses containing caspase recognition site (CRS) DIDGGETDG (SEQ ID NO 1) appeared to be attenuated in mice after intranasal immunization. Indeed, while in vitro experiments using MDCK cells as host cells demonstrated temperature sensitivity of influenza virus containing CRS, the same virus constructs also showed very weak replication in the lungs of the experimental group of mice and, more specifically, were found to be attenuated in that group of mice by a factor of more than 100 as compared to the control group that was infected using recombinant influenza virus bearing a 2A cleavage site instead of a CRS.
It is concluded from the experimental results that by inserting caspase recognition sequences into influenza NSl protein two goals have been achieved. First, attenuation of the virus in vitro and in vivo was achieved due to the impairment of the NSl protein induced by activated caspases during the viral replication cycle. Second, more precise and efficient post-translational cleavage and separation of the foreign sequence or sequences that were inserted into the NSl open reading frame (ORF) , from the functional N-terminal part of the NSl protein was achieved.
Notwithstanding the aforesaid, it shall be mentioned that previous attempts to rescue NS transfectants with inserts of more than 275 aa using plasmid only transfection systems frequently failed. Accordingly, in order to rescue
the GFP expressing vector it was necessary to improve the rescue system and to enhance its efficiency. This goal was achieved by applying co-transfection of additional plasmids expressing the proteins of the viral polymerase complex (RNP) .
Using GFP as an example for insertion of a heterologous POI it was confirmed on one hand that the recombinant NSl- GFP virus containing caspase recognition sites was replicating to high titers and was genetically stable while passaging in Vero cells, generating 100% of fluorescent plaques. On the other hand, however, it was found that the virus, although growing and expressing GFP in IFN competent cells, was losing GFP activity by generating various deletions within the recombinant NS gene. It may be concluded therefrom that the IFN antagonizing function of the NSl-GFP virus was partially compromised although the virus had an intact N-terminal part of the NSl protein which efficiently released from the GFP molecule by caspase cleavage.
While the NSl-GFP virus was growing in IFN competent cells it did not or only poorly replicate in wild type C57/bl mice, much like the delNSl virus which completely lacks the NSl ORF. However, when substituting PKR knock out mice for the wild type mice replication of NSl-GFP virus in the lungs proceeded up to a titer of equal or more than 104 PFU/g of lung tissue, as was also the case with delNSl virus. Moreover, even after two days of replication in mouse lungs the virus did not lose its capacity to express GFP.
Various reasons may be considered when trying to explain this attenuating effect in vivo. In the present case, the GFP insert may have some negative influence on the
formation of the NSl dimers, making NSl function to be less efficient and therefore promoting the activation of PKR.
Using the method of the present invention it was unambiguously demonstrated that the influenza virus can be engineered in such a way that foreign sequences which are even longer than the NSl protein itself can be expressed from the NSl reading frame and that such recombinant ' viruses can be successfully maintained and propagated to high titers in IFN deficient substrates such as Vero cells .
This new approach could be a promising strategy for the generation of live antiviral, preferably influenza virus- based, vaccines and vectors, and most preferably using NSl truncation technology as disclosed, e.g., in WO 01/64860, wherein NSl truncation occurs at or after aa position 125 by deletion of the N-terminal part of the NSl sequence or by insertion of one or more desired POI sequences after aa position 125. In addition, the vector constructs and viruses containing such contructs according to the present invention can be used as tools for screening of antiviral drugs against desired antigens, and where the POI is a marker substance, e.g. a fluorescent dye, also for tracking virus infections in animals and human subjects.
It is pointed out, however, that the concept of insertion of caspase recognition sites into a vector system for recombinant protein production is of a more general nature and may likewise be applicable to vectors other than influenza virus vectors, such as e.g. baculovirus or adenovirus vectors or other vector systems known in the art.
BRIEF DESCRIPTION OF THE FIGURES
FIG.l: Schematic drawing of the structure of a truncated recombinant NSl protein containing caspase recognition sites (CRS) .
FIG.2: Post-translational cleavage of the recombinant viral protein NSl-Caspase-ELDKWAS-ILl .
FIG.3: Virus yields in MDCK cells at 39°C after treatment with different caspase inhibitors. Ordinate: viral titers expressed in pfu/ml; abscisse: different caspase inhibitors; "w/o" = without; "general" means inhibitor Z-VAD FMK, which inhibits all caspases .
FIG.4: Viral growth in lungs of infected mice; ordinate = viral titers in pfu/ml; abscisse = days post infection; triangles = control virus (i.e. without
CRS), squares = experimental virus (i.e. with CRS).
Fig.5: Cleavage of recombinant NSl-GFP protein in infected cells. MDCK cells were infected with NSl-GFP virus in the presence (lanes 2 and 3) and absence (lane 1 and
4) of the universal caspase inhibitor Z-VAD-FMK. 12 h post infection, cells were lyzed, analyzed by Western blot and detected with anti-NSl mouse serum (lanes 1 and 2) and followed by alkaline phosphatase staining or anti-GFP rabbit serum (lanes 3 and 4) using a chemoluminiscence assay.
A = NSl-GFP fusion protein; B = cleaved GFP; C = cleaved NSl.
Fig.6: Viral growth in mouse lungs. PKR+/+ mice or PKR~/- mice were infected intranasally with 5*104 PFU/animal of the transfectant NSl-GFP virus. On day 2, mouse lungs were titrated using a limiting dilution assay on Vero cells and shown as geometric mean titer.
In order that the invention described herein may be more fully understood, the following examples are set forth. The examples are for illustrative purposes only and are not to be construed as limiting the present invention in any respect.
Example 1 : Preparation of recombinant negative strand influenza A viruses
The plasmid clones containing the caspase recognition site
(CRS) and gp-41 sequence have been prepared on the basis of the existing plasmid clone of influenza NS gene pUC19/NSPR (Egorov et al . , 1998, J Virol 72/8, 6437-41).
The sequence of CCS was inserted into the NSl protein ORF, at the position 400nt followed by the sequence of the protein of interest (designated LEI) consisting of HA leader peptide + ELDKWAS (SEQ ID NO 3) peptide sequence from GP-41 of HIV-1+ IL-I nanopeptide. As a second step, a final recombinant plasmid was constructed harboring a mutated influenza A/PR/8/34 NS gene flanked by the human polymerase I (Poll) promoter and Hepatitis Delta Virus (HDV) genomic ribozyme sequences.
This plasmid clone was used for the transfection of Vero cells. Syntheic chimeric NS gene transcribed by Poll polymerase in vivo (Vero cells) was rescued using special influenza virus helper viruses: PR8 DeINS (rf. WO
99/64571) or A/Singapore/l/57-del NS87 (rf . WO 02/24876) .
Transfected cells were infected with one of the listed viruses 24 hours after transfection (moi= 1) and the virus yield was subjected for the selection procedure in Vero cells. Because of the entire property of both helper viruses to be sensitive to interferon action (as a result of NSl deletions) human interferon-alpha (10 units/ml of media) have been used as selective pressure. After 2-3
passages in Vero cells in the presence of interferon chimeric NS mutants PR8-NS-caspase-LEI (HlNl) and Sing- NS-caspase-LEI (H2N2) were obtained. In contrast to the helper strains these viruses were not sensitive to the interferon action because of the functional RNA binding domain coded by the first 125 aa of NSl ORF.
In the functional map of the engineered NSl protein of the present invention it is indicated that the insertions are introduced after aa postion 125 and followed by a stop codon which has in effect that the remaining adjacent portion of the NSl gene segment rests untranslated.
Suitable recombinant protein constructs according to the present invention are represented in general by the schematic drawing of FIG. 1, while the invention disclosed herein is explicitly exemplified for the following recombinant protein construct (SEQ ID NO 3) that was prepared following the aforementioned protocol:
MLPSRRQRGGWDHAGQQKQGDKDIMDPNTVSSFQVDCFLWHVRKRVAD NSl < QELGDAPFLDRLRRDQKSLRGRGSTLGLDIETATRAGKQIVERILKEESD EALKMTMASVPASRYLTDMTLEEMSRDWSMLIPKQKVAGPLCIRMDQAIM DIDGGETDG MKTIIALSYIFCPALGQDLP ELDKWAS VQGEESNDK I*- CRS → I*- Leading Sequence-* | ELDKWAS | <•- IL-1→ \
Example 2 : Cleavage of a recombinant protein construct containing CRS
The recombinant protein construct described in Example 1 was further subjected to post-translational cleavage by caspase enzymes. Fig.2 mirrors the results of the western blot analysis, showing that the recombinant NSl protein containing CRS was efficiently cleaved by the activated
caspases after 12 hours of infection (lane 4 and 5) . When caspase inhibitor VAD was added (lane 6) protein cleavage was abolished.
MDCK cells were infected with recombinant influenza Sg/NSl-Caspase-ELDKWAS-ILl virus and analysed by western blot using mouse anti-NSl serum. Lane 1 shows the size of NS1/125 protein, containing just 125 NSl specific N- terminal amino acids remaining in the present constructs . Lane 3 and Lane 4 show the cleaved and uncleaved forms of the recombinant protein at 4 hours (lane 3) and 10 hours (lane 4) after infection; lane 5 shows cleavage of the NSl-Caspase-ELDKWAS-ILl protein 12 hours after infection in Vero cells; lane 6 shows the result when caspase inhibitor Z-VAD-FMK (Supplier: R&D Systems) was added to the maintenance medium, the result being failure of cleavage of the NSl-Caspase-ELDKWAS-ILl protein 12 hours after infection of Vero cells.
Example 3: Attenuation in vitro
Surprisingly it was found that insertion of the caspase cleavege sites into influenza NSl protein causes a temperature sensitivity (ts) of the virus in MDCK cells (Table 1) .
Vero cells and MDCK cells were infected with recombinant influenza A (HlNl) virus comprising the caspase recognition sites PR8-NS-Caspase-LEI (HlNl) or with a control virus PR8-NS2A-LEI (HlNl) (control) , lacking the CRS and comprising the 2A-cleavage site instead, at a moi=l. Infected cells were incubated at two temperatures 37°C and 390C for 24 hours. Caspase inhibitors were added to the culture media at a concentration of 0.25 μM. Viral
yields were measured by the titration on Vero cells at the permissive temperature of 370C.
Table 1: Temperature sensitivity of CRS-bearing recombinant virus
Vero cells MDCK cells
Viruses 370C 39°C 37° 39°C
PR8-NS2A-LEI (HlNl) (control) 5x10 6 3xlO6 IxIO6 2xlO4
PR8-NS-caspase-LEI (HlNl) 2x10 7 IxIO7 2xlO6 <102
The results presented in Table 1 demonstrate that CRS- containing virus had about a 104-fold reduction in growth at the elevated temperature of 390C as compared to the optimal growth temperature of 370C. This (ts) phenotype was expressed only in MDCK cells, but not in interferon deficient Vero cells .
Caspase 8 and 9 are probably involved in the mechanism of this (ts) phenotype expression, because addition of caspase 8 and 9 as well as of the general caspase inhibitor to the tissue culture media have increased the viral titers by a factor of more than 100 as compared to the control groups where DMSO solution without inhibitor or other caspase inhibitors were added (see Fig.3).
Example 4 : Attenuation in mice C57 black
In order to prove whether the attenuated, i.e. ts, phenotype observed in vitro caused by insertion of caspase recognition sites (CRS) into recombinant influenza virus
constructs would also be detectable in vivo, a mouse experiment was carried out.
Surprisingly, it was found indeed that influenza A and B recombinant viruses containing the CRS DIDGGETDG (SEQ ID NO 1) appeared to be attenuated in mice after intranasal immunization. Fig.4 shows the growth curves of two similar recombinant influenza viruses, differing primarily in the presence or absence of CRS. The control virus PR8-NS-2A- LEI (HlNl) does not have this site and replicates efficiently up to 3.5 log/g in the lung tissues. The experimental virus PR8-NS-caspase-LEI containing CRS displays very weak replication in the lungs and is more than 100 times attenuated in the experimental group of mice .
Example 5 : Rescue of influenza virus expressing gfp from the NSl reading frame
Viruses and cells: Vero and MDCK cell lines originated from the American Type Culture Collection (ATCC) . Vero cells were adapted to and further cultivated in DMEM/Ham' s F12 (Biochrom F4815) with 4 mM L-glutamine and protein-free supplement. MDCK cells were cultivated in DMEM/Ham' s F12 medium containing 2 % heat inactivated fetal calf serum (FCS, HyClone SH30071) and 4 mM L-glutamine. Influenza virus A/PR/8/34 (HlNl)
(PR8) and NS mutants A/PR8/delNSl (delNSl), A/PR8/NS1-125
(NS1-125) and A/PR8/NSl-del40-80 (NSl-del40-80) (Fig.l) were obtained in Vero cells by using the transfection protocol as described in Egorov et al.,1998. All viruses were grown and titrated in Vero cells at 37° C.
Construction of plasmids:
Viral RNA was extracted from influenza PR8, reverse transcribed and served as a template for subsequent
amplification of the NS gene by PCR. The NS sequence was blunt end cloned between the Poll promoter and hepatitis delta virus (HDV) genomic ribozyme and designated as pPolI-NS-HDV. Oligonucleotides coding for the caspase recognition site, i.e. 5 ' -ATTGATGGAGGTGAAACTGATGGG-S' (SEQ ID NO 6) and 5'-CCCATCAGTTTCACCTCCATCAAT-S' (SEQ ID NO 7), were synthesized, annealed and blunt end ligated into plasmid pPolI-NS-HDV after nucleotide position 400 of NS. The resulting plasmid was named pPol-NS125Casp-HDV.
Insertion of the GFP encoding sequence (Quantum' s SuperGlo™ GFP, extracted from Vector pQBI25-fcl, Qbiogene) into plasmid pPol-NS125Casp-HDV downstream the CRS resulted in the plasmid pPol-NS-Casp-GFP-HDV. The expression plasmids for PBl, PB2, PA and NP influenza proteins were obtained by cloning the corresponding PR8 genes into the vector pTriEx-1 (Novagene) under the chicken actin promoter; they were designated pTriEx-PBl, pTriEx-PB2, pTriEx-PA and pTriEx-NP, respectively.
Generation of transfectant viruses:
90% confluent Vero cells were transfected with lμg of each plasmid pPol-NS-Casp-GFP-HDV, pTriEx-NP, pTriEx-PA, pTriEx-PBl and pTriEx-PB2 using the nucleofection technique (Amaxa) , according to the manufacturer's instruction manual. 24 hours later, cells were examined for GFP expression and infected with delNSl helper virus
(MOI = 0,1). Eight hours post infection (p.i.), 3 U of human IFN-α (NIBSC 1st International Standard 1999, human leukocyte derived) per ml culture medium were added and cells were incubated 48 hours at 37°C. The supernatant was passaged twice in Vero cells in the presence of IFN-α at a concentration of 3 U/ml and plaqued in Vero cells. Plaques containing the correct NSl-GFP gene were identified by RT-
PCR. Following two rounds of plaque purification, in which plaques were routinely examined for GFP expression, a pure virus could be isolated. This virus was designated as A/PR8/NS1-125GFP (NSl-GFP) , analyzed by RT-PCR and the correct sequence was confirmed by nucleotide sequence analysis .
Viral replication in mice lungs:
Four to six weeks old C57BL/6 mice or PKR knock out mice (PKR-/-) , which were derived from C57BL/6 mice by the targeted deletion of PKR (Yang et al., 1995) were infected intranasally (i.n.) with 5*104 PFU/animal of the virus under ether anesthesia. At day two, mice were sacrificed and lungs aseptically removed. A 10% tissue extract in PBS was prepared by grinding the tissue sample with a rotor homogenizer. The suspension was centrifuged at 2,000 g for five minutes and the viral yield of the supernatants was determined by limiting dilution assay in Vero cells.
Polyacrylamide gel electrophoresis and Western blot analysis :
SDS PAGE of virus preparations was carried out using Tris- Glycine 16% gels (Anamed) . Western blotting was performed by electrophoretic transfer of the proteins from the gel to a polyvinyl difluoride membrane (Millipore) for two hours at 400 mA. After overnight blocking in TPBS (PBS with 0.1% Tween 20) containing 3% of skim milk, the membrane was incubated for one hour with specific mouse anti-NSl-GST or rabbit anti-GFP antisera (Clontech) and diluted 1:5,000 in TPBS buffer containing 1% of skim milk. After washing with TPBS, the membrane was either incubated for one hour with anti-mouse alkaline phosphatase or anti- rabbit peroxidase labeled conjugate (Sigma) diluted 1:40,000 in TPBS containing 1% of skim milk. The blots were developed in staining buffer (100 mM Tris HCl/ 100 mM
NaCl; 5 mM MgCl2, pH 9.5) with nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate or by ECL plus Western Blotting Detection system (Amersham) for chemoluminiscence, respectively.
Results :
Growth of influenza NS mutants in Vero cells treated with human IFN-α:
To determine the IFN sensitivity of NS mutants, Vero cells were infected with the wild type PR8 virus or three different NS mutants containing either only 125 N-terminal aa (NS1-125), lacking NSl ORF (delNSl) or harboring a 40 aa deletion (NSl-del40-80) in the N-terminal part of the molecule (Table 2) .
Table 2: Growth comparison of influenza virus NSl mutants
Table 2 shows the growth of recombinant virus mutants containing different NSl truncations on Vero cells in the absence or presence of externally added human IFN-α. Titers of influenza PR8 virus and NS mutants grown in the presence or absence of human IFN-α in Vero cells were determined 36 h post infection using a plaquing assay on Vero cells.
The infected cells were incubated either without addition of human IFN-α to the cell culture medium or in the presence of 3 U/ml human IFN-α, whereupon the viral titers were compared 36 h post infection. It was found, that mutants delNSl and NSl-del40-80 containing an impaired RNA binding/dimerization domain were dramatically attenuated with regard to growth under the pressure of IFN-α, whereas the wild type virus as well as the NS1-125 mutant containing an intact RNA binding domain showed almost similar titers when incubated in the presence or absence of IFN-α (Tab.2). Thus, the first N-terminal 125 amino acids of the NSl protein may possibly serve as a resistance factor responsible for antagonizing IFN action.
Rescuing GFP expressing influenza NS vector:
Vero cells were transfected with plasmids expressing the components of the influenza RNP complex and the plasmid pPol-NS-Casp-GFP-HDV encoding chimeric vRNA in which GFP was cloned as the protein of interest (POI) into the NSl reading frame after aa 125, according to the general concept depicted in Fig.l. In addition, an artificial caspase recognition site (DIDGGETDG) was introduced between those two proteins in order to provide posttranslational separation of the molecules.
Transfected cells were infected with an IFN-sensitive helper virus (delNSl) and the virus yield was harvested 48 h post infection. This yield contained at least 102 PFU/ml progeny of the "fluorescent virus" and 105 PFU/ml of the helper virus, determined by limiting dilution assay in
Vero cells without IFN-α treatment. Two passages in Vero cells in the presence of IFN-α were performed to enrich the population of the transfectant virus and a pure GFP expressing plaque was isolated. After a further two rounds
of plaque purification in Vero cells, in which plaques were routinely examined for GFP expression, a pure clone of GFP expressing virus was isolated and designated as A/PR8/NS1-125GFP (NSl-GFP) .
This virus, when applied at MOI=I, was able to induce expression of GFP as early as six hours post infection in Vero and MDCK cells with full manifestation 24h post infection. By Western blot analysis it was confirmed that insertion of the CRS indeed resulted in posttranslational cleavage of the GFP from the N-terminal part of the NSl protein (Fig.5). Addition of general caspase inhibitor Z- VAD-FMK (R&D Systems) to the medium inhibited cleavage, thus confirming that cleavage occurred due to host cells caspase activity.
Growth capacity of NS-GFP expression vector:
As expected, the recombinant NSl-GFP strain had an IFN resistant phenotype and was capable of replicating in MDCK cells and ten days old embryonated chicken eggs as efficient as in Vero cells up to titers of 106 -107 PFU/ml. However, the genetic stability of the construct was not equal in IFN deficient and in IFN competent cell substrates. In contrast to Vero cells, passages in MDCK cells caused evolution of NSl-GFP deletion mutants at a fairly high rate accompanied by the loss of GFP expression after several passages.
Replication in mice: Virus NSl-GFP revealed a full attenuation in the wild type mice (C57BL/6) as compared to the NS125 mutant, which reached a titer of 5*104 PFU/g in the lung tissues two days post infection (Fig.6). However, the infection of PKR knock out (PKR-/-) mice, previously shown to support the replication of the delNSl virus, resulted in the
replication of the GFP expressing vector in lung tissues to 4*104 PFU/g, detected two days post infection. Furthermore, even after two days of replication in mouse lungs, the virus was still expressing GFP as confirmed by titration in Vero cells.
References :
Alnemri ES, Livingston DJ, Nicholson DW, Salvesen G, Thornberry NA, Wong WW, Yuan J. 1996. Human ICE/CED-3 protease nomenclature. Cell. 18 ; 87 (2 ) : 171.
Egorov A, Brandt S, Sereinig S, Romanova J, Ferko B, Katinger D, Grassauer A, Alexandrova G, Katinger H and T Muster. 1998. Influenza A transfectant viruses with long deletions in the NSl protein grow efficiently in Vero cells. J Virol. 72 (8 ): 6437-6441.
Zhirnov OP, Konakova TE, Garten W and H-D Klenk. 1999. Caspase-dependent N-terminal cleavage of influenza virus nucleocapsid protein in infected cells. J Virol. 73 (12 ): 10158-63.
Yang, Y. L., Reis, L. F., Pavlovic, J., Aguzzi, A., Schafer, R., Kumar, A., Williams, B. R., Aguet, M., and Weissmann, C. (1995) . Deficient signaling in mice devoid of double- stranded RNA-dependent protein kinase. Embo J 14(24), 6095- 106.
Claims
1. A nucleotide sequence encoding a recombinant protein product characterized in that the nucleotide sequence contains at least one sequence section that encodes one or more caspase recognition sites and that is located in between and links together a first part of the nucleotide sequence encoding a first part of the protein product and a second part of the nucleotide sequence encoding a second part of the protein product.
2. The nucleotide sequence according to claim 1, wherein said first part of the nucleotide sequence encodes a truncated NSl protein, preferably the first 125 N-terminal amino acids of the NSl protein.
3. The nucleotide sequence according to claim 1 or 2, wherein said second nucleotide sequence encodes a peptide or protein of interest (POI), said POI preferably being a tumor antigen or an antigenic determinant of a viral or bacterial protein, the viral or bacterial protein preferably being selected from the group consisting of gp41 of HIV-I, gpl20 of HIV-I, Nef protein of HIV-I, HA of influenza virus, NA of influenza virus, TBC antigen, and malaria antigen.
4. The nucleotide sequence according to any one of claims 1 to 3, wherein said sequence section comprises two caspase recognition sites spaced apart by a glycine residue, the sequence section preferably being SEQ ID NO 1.
5. A recombinant nucleotide vector, preferably a viral recombinant vector, comprising a nucleotide sequence as defined in any one of claims 1 to 4.
6. The vector according to claim 5, characterized in that it renders a virus containing said vector attenuated, particularly temperature sensitive, in MDCK cells but not in interferon deficient Vero cells.
7. The vector according to claim 5 or 6, characterized in that it renders a virus containing said vector attenuated in vivo.
8. A recombinant virus, preferably recombinant influenza virus, characterized in that it comprises a nucleotide sequence as defined in any one of claims 1 to 4 or a vector as defined in any one of claims 5 to 7.
9. The virus according to claim 8, characterized in that it is attenuated, particularly temperature sensitive, in MDCK cells but not in interferon deficient Vero cells.
10. The virus according to claim 8 or 9, characterized in that it is attenuated in vivo.
11. A vaccine comprising a vector as defined in any one of claims 4 to 6 or a virus as defined in any one of claims 7 to 9.
12. The vaccine according to claim 11, characterized in that it is attenuated in vivo.
13. The vaccine according to claim 11 or 12, for prophylactic or therapeutic application against tumors or viral infections.
14. Use of a nucleotide sequence encoding a caspase recognition site, preferably encoding a combination of two or more caspase recognition sites, for providing a cleavage site to a nucleotide vector, for post- translational cleavage of at least one peptide or protein of interest from a protein product encoded by said vector,
15. A composition comprising a nucleotide sequence as defined in any one of claims 1 to 4.
16. A composition comprising a vector as defined in any¬ one of claims 5 to 7.
17. A composition comprising a virus defined in any one of claims 8 to 10.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03013509 | 2003-06-13 | ||
EP03013509.9 | 2003-06-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004111249A2 true WO2004111249A2 (en) | 2004-12-23 |
WO2004111249A3 WO2004111249A3 (en) | 2005-02-10 |
Family
ID=33547589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/006225 WO2004111249A2 (en) | 2003-06-13 | 2004-06-09 | Protein constructs containing caspase recognition sites |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2004111249A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101250005B1 (en) * | 2010-12-31 | 2013-04-03 | 연세대학교 산학협력단 | Method of preparing live viral vaccines by genetic engineering of viral genome |
WO2015063085A1 (en) | 2013-10-28 | 2015-05-07 | Thomas Muster | Novel influenza virus vector for virotherapy |
WO2016065174A1 (en) * | 2014-10-22 | 2016-04-28 | Seed Research And Development Llc | Caspase probes for detection of apoptosis |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000073437A1 (en) * | 1999-05-27 | 2000-12-07 | Merck Frosst Canada & Co. | Assays for caspase activity using green fluorescent proteins |
WO2001020989A1 (en) * | 1999-09-22 | 2001-03-29 | Mayo Foundation For Medical Education And Research | Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family |
WO2001064860A2 (en) * | 2000-03-02 | 2001-09-07 | Polymun Scientific Immunbiologische Forschung Gmbh | Recombinant influenza a viruses |
-
2004
- 2004-06-09 WO PCT/EP2004/006225 patent/WO2004111249A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000073437A1 (en) * | 1999-05-27 | 2000-12-07 | Merck Frosst Canada & Co. | Assays for caspase activity using green fluorescent proteins |
WO2001020989A1 (en) * | 1999-09-22 | 2001-03-29 | Mayo Foundation For Medical Education And Research | Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family |
WO2001064860A2 (en) * | 2000-03-02 | 2001-09-07 | Polymun Scientific Immunbiologische Forschung Gmbh | Recombinant influenza a viruses |
Non-Patent Citations (2)
Title |
---|
FERKO BORIS ET AL: "Hyperattenuated recombinant influenza A virus nonstructural-protein-encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice" JOURNAL OF VIROLOGY, vol. 75, no. 19, October 2001 (2001-10), pages 8899-8908, XP002309937 ISSN: 0022-538X * |
KITTEL CHRISTIAN ET AL: "Rescue of influenza virus expressing GFP from the NS1 reading frame" VIROLOGY, vol. 324, no. 1, 20 June 2004 (2004-06-20), pages 67-73, XP004512673 ISSN: 0042-6822 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101250005B1 (en) * | 2010-12-31 | 2013-04-03 | 연세대학교 산학협력단 | Method of preparing live viral vaccines by genetic engineering of viral genome |
US8834892B2 (en) | 2010-12-31 | 2014-09-16 | Industry-Academic Cooperation Foundation, Yonsei University | Method of preparing live viral vaccines by genetic engineering of viral genome |
WO2015063085A1 (en) | 2013-10-28 | 2015-05-07 | Thomas Muster | Novel influenza virus vector for virotherapy |
US10125374B2 (en) | 2013-10-28 | 2018-11-13 | Blue Sky Vaccines Gmbh | Influenza virus vector for virotherapy |
WO2016065174A1 (en) * | 2014-10-22 | 2016-04-28 | Seed Research And Development Llc | Caspase probes for detection of apoptosis |
Also Published As
Publication number | Publication date |
---|---|
WO2004111249A3 (en) | 2005-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kittel et al. | Rescue of influenza virus expressing GFP from the NS1 reading frame | |
US11471524B2 (en) | Recombinant RSV with silent mutations, vaccines, and methods related thereto | |
ES2321651T3 (en) | DEFICIENT REPLICATION RNA VIRUSES AS VACCINES. | |
US20030027321A1 (en) | Recombinant RSV virus expression systems and vaccines | |
JP7311872B2 (en) | Chimeric RSV, Immunogenic Compositions, and Methods of Use | |
US20090175899A1 (en) | Recombinant rsv virus expression systems and vaccines | |
EP1067179A1 (en) | Method to select attenuated paramyxoviridae useful for vaccines and therapeutics | |
US20220125909A1 (en) | Chimeric rsv and hmpv f proteins, immunogenic compositions, and methods of use | |
KR100584831B1 (en) | Pneumovirus ns proteins antagonising the interferon ifn response | |
WO2004111249A2 (en) | Protein constructs containing caspase recognition sites | |
EP1075524A2 (en) | Attenuated influenza viruses | |
US6723559B2 (en) | Recombinant segmented negative strand virus containing bicistronic vrna segment with a duplication of its 3′ noncoding flanking sequence, and vaccines and therapeutic compositions containing the same | |
US20240082385A1 (en) | Rsv vaccines and methods of administering same | |
US20050158340A1 (en) | Recombinant RSV virus expression systems and vaccines | |
AU2003200297B2 (en) | Recombinant RSV virus expression systems and vaccines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |